Modern Drug House Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Modern Drug House Pharmaceutical Export Portfolio Dataset — 5 Products, $1.7M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Modern Drug House — Pharmaceutical Exporter Profile (2026) | 5 Products, $1.7M Trade | TransData Nexus

Modern Drug House

Indian Pharmaceutical Exporter · Diabetes & Endocrine Specialist · $1.7M Total Trade · DGFT Verified

Modern Drug House is an Indian pharmaceutical exporter with a total trade value of $1.7M across 5 products in 4 therapeutic categories. Based on 156 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Insulin ($1.1M), Cyclosporine ($484.4K), Plasma ($46.7K).

Modern Drug House — Export Portfolio & Destination Treemap

Modern Drug House pharmaceutical export portfolio — 5 products across 4 therapeutic categories. Source: Indian Customs (DGFT).

Who is Modern Drug House? — Company Overview & Market Position

Established in 1962, Modern Drug House is a Mumbai-based pharmaceutical exporter specializing in the distribution of vaccines and life-saving pharmaceutical products. The company operates as a partnership firm, with an annual turnover ranging between ₹25 crore and ₹100 crore. Its registered office is located at 3-B, 1st Floor, Prime Plaza, JV Patel Compound, Balashet Madhurkar Marg, Elphinstone Road, Mumbai - 400013, Maharashtra, India.

The firm's Import Export Code (IEC) is 0312031611, and it holds FDA-approved drug licenses numbered 21B WZ 28/1609 and 20B WZ 28/1641. The company is managed by a team of professionals, including sourcing agents, medical experts, quality analyzers, and warehousing and packaging personnel.

What Does Modern Drug House Export? — Product Portfolio Analysis

Top Products by Export Value

1Insulin$1.1M 2Cyclosporine$484.4K

Product Portfolio — Top 5 by Export Value

Modern Drug House exports 5 pharmaceutical products across 4 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Insulin	Diabetes & Endocrine	$1.1M	72	1.5%	7
2	Cyclosporine	Immunosuppressants	$484.4K	29	4.0%	5
3	Plasma	Other	$46.7K	24	1.7%	7
4	Antitoxin	Other	$38.6K	16	0.3%	12
5	Nivolumab	Advanced Oncology	$28.7K	15	1.3%	4

Modern Drug House exports 5 pharmaceutical products across 4 therapeutic categories with a total export value of $1.7M. The top category is Diabetes & Endocrine (65.3% of portfolio), followed by Immunosuppressants (28.1%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Modern Drug House — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Modern Drug House does not operate its own manufacturing facilities. Instead, it sources pharmaceutical products from a network of reputable manufacturers. The company emphasizes quality assurance by selecting vendors based on their market credibility, product quality, and financial stability. Notable authorized dealerships include Novartis, Bharat Serum, Abbott Pvt Ltd., Chiron Panacea, Kamada Pvt Ltd., Panacea Biotech, GlaxoSmithKline, Synergy India Pvt Ltd., Serum Institute of India, VHB Life Science Pvt Ltd., John Wyeth & Brother Ltd., Bio-Med Biological Pvt. Ltd., Merck Sharp & Dohme (MSD), Bharat Biotech International Pvt. Ltd., and Sanofi Pasteur Pvt. Ltd.

3Key Leadership

The leadership team at Modern Drug House includes:

Mr. Darshan Parekh: Global Sales Director, overseeing international sales operations.

Mr. Bharat M. Parekh: Promoter and partner, contributing to strategic decision-making.

Mr. Atul Manilal Parekh: GST Partner, involved in financial and compliance aspects.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Modern Drug House Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Modern Drug House's export activities are primarily focused on finished pharmaceutical formulations, including vaccines and injectables. The company has established a robust network of manufacturers to ensure timely distribution to both Indian and overseas customers. While specific regulatory filings and approvals in markets such as the United States, European Union, United Kingdom, Australia, and Japan are not publicly disclosed, the company's adherence to international quality standards and its partnerships with globally recognized manufacturers suggest compliance with regulatory requirements in these regions.

2Emerging Markets

Modern Drug House has expanded its reach to emerging markets, including Africa, Latin America, and Southeast Asia. The company's extensive network of manufacturers and its commitment to quality assurance have facilitated its penetration into these regions. While specific details regarding WHO prequalification are not available, the company's partnerships with reputable manufacturers and its adherence to international quality standards position it favorably for access to these markets.

3Geographic Strategy

Modern Drug House — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Modern Drug House holds FDA-approved drug licenses numbered 21B WZ 28/1609 and 20B WZ 28/1641, indicating compliance with FDA regulations for the distribution of pharmaceutical products. However, specific details regarding FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly disclosed.

2WHO & EU GMP

While specific information regarding WHO prequalification and EU Good Manufacturing Practice (GMP) certificates is not available, Modern Drug House's partnerships with globally recognized manufacturers suggest adherence to international quality standards. The company's commitment to quality assurance and its extensive network of procurement partners further support its compliance with WHO and EU GMP guidelines.

3CDSCO & Indian Regulatory

Modern Drug House operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds an Import Export Code (IEC) of 0312031611 and FDA-approved drug licenses numbered 21B WZ 28/1609 and 20B WZ 28/1641, indicating compliance with Indian regulatory requirements. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly disclosed.

Modern Drug House — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Modern Drug House operates in a competitive landscape with several key players in the pharmaceutical distribution sector. While specific market share data is not publicly available, the company's extensive network of authorized dealerships and its partnerships with multinational manufacturers position it as a significant player in the market. The company's focus on quality assurance and timely delivery further enhances its competitive edge.

2Key Differentiators

Modern Drug House's key differentiators include its extensive network of authorized dealerships, partnerships with globally recognized manufacturers, and a strong commitment to quality assurance. The company's ability to source and distribute a comprehensive range of vaccines and life-saving pharmaceutical products positions it uniquely in the market.

3Strategic Position

Modern Drug House's current strategic direction focuses on expanding its global footprint through partnerships with a diverse range of manufacturers. The company's emphasis on quality assurance and timely delivery supports its strategy of becoming a trusted distributor of vaccines and pharmaceutical products worldwide. Future outlooks suggest continued growth and expansion into emerging markets, leveraging its existing network and expertise.

Buyer Due Diligence Brief — Evaluating Modern Drug House as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Modern Drug House has established a robust network of suppliers, including authorized dealerships with multinational manufacturers such as Novartis, Bharat Serum, Abbott Pvt Ltd., Chiron Panacea, Kamada Pvt Ltd., Panacea Biotech, GlaxoSmithKline, Synergy India Pvt Ltd., Serum Institute of India, VHB Life Science Pvt Ltd., John Wyeth & Brother Ltd., Bio-Med Biological Pvt. Ltd., Merck Sharp & Dohme (MSD), Bharat Biotech International Pvt. Ltd., and Sanofi Pasteur Pvt. Ltd. The company's consistent export volume and adherence to international quality standards indicate a reliable and consistent track record.

2Certifications to Verify

Importers should verify the following certifications when engaging with Modern Drug House:

FDA Drug License Numbers: 21B WZ 28/1609 and 20B WZ 28/1641.

Import Export Code (IEC): 0312031611.

These certifications can be verified through the respective regulatory bodies' official channels.

Due Diligence Checklist

Frequently Asked Questions — Modern Drug House

How many pharmaceutical products does Modern Drug House export from India?

Modern Drug House exports 5 pharmaceutical products across 4 therapeutic categories. The top exports are Insulin ($1.1M), Cyclosporine ($484.4K), Plasma ($46.7K), Antitoxin ($38.6K), Nivolumab ($28.7K). Total export value is $1.7M.

What is Modern Drug House's total pharmaceutical export value?

Modern Drug House's total pharmaceutical export value is $1.7M, based on 156 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Modern Drug House cover?

Modern Drug House exports across 4 therapeutic categories. The largest are Diabetes & Endocrine (65.3%, 1 products), Immunosuppressants (28.1%, 1 products), Other (5.0%, 2 products).

Get Full Modern Drug House Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.